BioCatalystWatch
SPROWorkspace / SPRO / OverviewCompany library

Spero Therapeutics, Inc.

Spero Therapeutics, Inc. (SPRO)

Price
Market cap
Next catalystQ2 2027, subject to FDA clearance of the U.S. INDSP001 — planned IgG4-RD Phase 2 study · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

SP001

CD40L

PreINDP1P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

SP001

CD40L

PreINDP1P3FilingApproved
Upcoming / outlook

Other pipelines

SP001

CD40L

SP001

CD40L

Approved / commercial

History / paused

SP001

CD40L

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

SPRO PR & News

PR & News

SPRO SEC archive